We included in this cohort study 174 patients with HCC who were treated with targeted agents approved for the second-line treatment of HCC; anti-programmed death receptor-1 (PD1) antibodies +/– anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) antibodies; anti-PD1 antibodies + targeted agents +/– anti-CTLA4 antibodies; other investigational treatments not reaching the approval for treatment of HCC. Here, CTLA4 is linked to hepatocellular carcinoma.